Prednisone

Generic Name
Prednisone
Brand Names
Deltasone, Rayos, Winpred
Drug Type
Small Molecule
Chemical Formula
C21H26O5
CAS Number
53-03-2
Unique Ingredient Identifier
VB0R961HZT
Background

A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication

Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions
Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
Associated Therapies
Palliative Treatment

High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Phase 3
Conditions
First Posted Date
2004-01-27
Last Posted Date
2013-09-20
Lead Sponsor
Lymphoma Trials Office
Target Recruit Count
500
Registration Number
NCT00003578
Locations
🇨🇿

Charles University Hospital, Prague (Praha), Czech Republic

🇬🇧

City Hospital - Birmingham, Birmingham, England, United Kingdom

🇳🇴

Norwegian Radium Hospital, Oslo, Norway

and more 69 locations

Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 1
Completed
Conditions
First Posted Date
2004-01-23
Last Posted Date
2013-06-24
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
24
Registration Number
NCT00003541
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Phase 2
Conditions
First Posted Date
2003-12-17
Last Posted Date
2013-12-04
Lead Sponsor
Amgen
Registration Number
NCT00005959
Locations
🇺🇸

Cancer and Blood Institute of the Desert, Rancho Mirage, California, United States

🇺🇸

Oncology/Hematology Care, Inc., Cincinnati, Ohio, United States

🇺🇸

Intermountain Hematology/Oncology Associates, Inc., Salt Lake City, Utah, United States

and more 24 locations

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Phase 2
Completed
Conditions
First Posted Date
2003-12-02
Last Posted Date
2023-06-22
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
38
Registration Number
NCT00003388
Locations
🇺🇸

Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States

🇺🇸

Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States

🇺🇸

Raritan Bay Medical Center, Perth Amboy, New Jersey, United States

and more 2 locations

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

First Posted Date
2003-11-24
Last Posted Date
2013-08-26
Lead Sponsor
Children's Oncology Group
Target Recruit Count
2078
Registration Number
NCT00002812
Locations
🇺🇸

Children's Hospital of Columbus, Columbus, Ohio, United States

🇺🇸

Ireland Cancer Center, Cleveland, Ohio, United States

🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

and more 32 locations

Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL

Phase 2
Completed
Conditions
First Posted Date
2003-11-06
Last Posted Date
2012-05-15
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
43
Registration Number
NCT00072007
Locations
🇨🇭

Hopital des Cadolles, Neuchatel, Neuchatel, Switzerland

🇨🇭

Spitaeler Chur AG, Chur, Switzerland

🇨🇭

Kantonsspital - St. Gallen, St. Gallen, Switzerland

and more 8 locations

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

First Posted Date
2003-11-05
Last Posted Date
2016-07-13
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
59
Registration Number
NCT00005964
Locations
🇺🇸

Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, United States

🇺🇸

Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States

🇺🇸

State University of New York - Upstate Medical University, Syracuse, New York, United States

and more 44 locations

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma

First Posted Date
2003-10-28
Last Posted Date
2013-02-08
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
120
Registration Number
NCT00003595
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

🇺🇸

San Francisco General Hospital Medical Center, San Francisco, California, United States

and more 10 locations
© Copyright 2024. All Rights Reserved by MedPath